Results 141 to 150 of about 35,970 (259)

Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study [PDF]

, 2005
A Gibbs, Trevor Markham, Ceara AE Walsh, Barry Bresnihan, Douglas J. Veale, Oliver FitzGerald   +5 more
openalex   +1 more source

New cases expand the genotype, phenotype and therapeutic landscape of H syndrome

British Journal of Haematology, EarlyView.
Clément Triaille, Julie Beauchemin, Philippe M. Campeau, Hugo Chapdelaine, Julie Dery, Maria Kondyli, Grant Mitchell, Julie Powell, Sophie Turpin, Guilhem Cros, Fabien Touzot   +10 more
wiley   +1 more source

Characterization of Second‐Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry

ACR Open Rheumatology, Volume 7, Issue 11, November 2025.
Objective We performed a real‐world characterization of patients with rheumatoid arthritis (RA) who initiate a JAK inhibitor (JAKi) and switch to a subsequent therapy and examination of factors associated with the use of another JAKi/therapy with another mechanism of action (MoA).
Joshua F. Baker, Kristi V. Mizelle, Wassim Saikali, Page C. Moore, Hyung‐Joo Kang, David Gruben, Ahmed Shelbaya, Lori Stockert, Jacqueline O'Brien   +8 more
wiley   +1 more source

THU0570 Anakinra as a successful treatment of idiopathic recurrent pericarditis: taper or not to taper? case series at the university of southern california [PDF]

, 2017
PS Chhibar, Glenn R. Ehresmann
openalex   +1 more source

Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial [PDF]

, 2021
Lennie Derde
openalex   +1 more source

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project

Biologics: Targets & Therapy, 2009
Kylie Thaler1, Divya V Chandiramani2, Richard A Hansen2, Gerald Gartlehner11Department for Evidence-based Medicine and Clinical Epidemiology, Danube University Krems, Krems, Austria; 2UNC Eshelman School of Pharmacy, University of North Carolina
Kylie Thaler, Divya V Chandiramani, Richard A Hansen, et al   +3 more
doaj  

Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial [version 1; peer review: 1 approved, 2 approved with reservations]

Wellcome Open Research
Background Novel host-directed therapies are urgently needed for patients with dengue, particularly those at high risk of developing severe disease.
Angela McBride, Huynh Thi Le Duyen, Nguyen Thanh Phong, Truong Ngoc Trung, Sophie Yacoub, Ronald Geskus, Tran Bang Huyen, Evelyne Kestelyn, Dang Trong Thuan, Nguyen Thi My Linh, Tran Thi Dong Vien, Nguyen Thi Cam Huong, Phan Vinh Tho, Nguyen Minh Nguyet, Vo Thi My Hoa, Nguyen Lam Vuong, Phan Tu Qui, Dong Thi Hoai Tam, James Watson, Huynh Trung Trieu   +19 more
doaj   +1 more source

FRI0611 ACUTE AND LONG-TERM EFFICACY OF IL-1 INHIBITOR ANAKINRA IN IDIOPATHIC AND SECONDARY PERICARDITIS IN PATIENTS REFRACTORY OR INTOLERANT TO CONVENTIONAL THERAPY [PDF]

, 2019
Muhammad Hamza Saad Shaukat, Sukhraj Singh, Kathryn Davis, Mikhail Torosoff, Ruben Peredo-Wende   +4 more
openalex   +1 more source

Chimeric Antigen Receptor T‐Cell Therapy and Autoimmune Diseases in the Nervous System

Immunity, Inflammation and Disease, Volume 13, Issue 11, November 2025.
ABSTRACT Introduction Chimeric antigen receptor T‐cell (CAR‐T) therapy, a revolutionary immunotherapy originally developed for hematologic malignancies, has recently gained attention for its potential in treating autoimmune diseases. Increasing evidence suggests that CAR‐T cells can precisely target pathogenic immune populations, offering durable ...
Shun‐yu Yao, Miao‐qiao Du, Huan Yang, Qiu‐ming Zeng, Hao Zhou, Xiuli Zhang, Sugimoto Kazuo, Jia Liu, Lan‐xin Lin, Xu‐hui Kang, Dai‐yi Jiang, Yong Peng   +11 more
wiley   +1 more source

Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study

Therapeutic Advances in Hematology
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening, hyperinflammatory syndrome for which etoposide-based regimens have historically been the standard of care.
Benjamin J. Lee
doaj   +1 more source